Skip to main content
. Author manuscript; available in PMC: 2014 Jun 24.
Published in final edited form as: Biol Blood Marrow Transplant. 2009 Sep 1;15(11):1431–1438. doi: 10.1016/j.bbmt.2009.07.008

Table 4.

N Median Survival Time (95% CI) P-value
HSCT Chemotherapy
A) Age<50, CR1 duration >36 weeks 48 13.54 (8.69, 31.2) 5.15 (4.0, 16.6) 0.03
B) Age<50, CR1 duration ≤36 weeks 57 5.05 (4.29, 10.43) 2.88 (1.44, 3.77) 0.0005
C) Age<50, CR1 duration =0 weeks 35 5.71 (4.59, NA) 1.84 (1.34, 3.15) 0.0002
D) Age≥50, CR1 duration >36 weeks 100 6.13 (3.93, 8.98) 3.48 (2.62, 6.0) 0.17
E) Age≥50, CR1 duration ≤36 weeks 85 2.47 (1.9, NA) 2.66 (1.97, 3.48) 0.05
F) Age≥50, CR1 duration =0 weeks 71 5.85 (4.39, NA) 2.26 (1.9, 3.57) 0.15

Overall survival comparison between HSCT cohort and non-HSCT cohort by multiple subgroup analyses for patients according to age and CR1 duration.